New Gynecologic Oncology Clinical Trials Sylvester Comp Cancer Center Sylvester Comp Cancer Center
- July 14, 2016
- Clinical Trials
The Sylvester Comprehensive Cancer Center’s Division of Gynecologic Oncology’s Research Program is opening 4 new clinical trials for women with ovarian, cervical and endometrial cancer. These include two surgical trials evaluating the role of sentinel lymph node biopsy in cervical and endometrial cancer and two immunotherapy trials in first-line and recurrent ovarian cancer.
They continue to offer other immunotherapy trials in ovarian and cervical cancer. See list below.
If you have any questions, contact Michelle Mikhail (m.mikhail@med.miami.edu) or Yvonne Dinh (y.dinh@med.miami.edu)
NEW – Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANGTM (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer. PI: Brian Slomovitz
NEW – Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek – Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects with Cancer of the Cervix undergoing Lymph Node Dissection PI: Matt Pearson
NEW – Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (KEYNOTE -100) , PI: Marilyn Huang
NEW – The Validity of Sentinel Lymph Node Dissection (SLND) in Patients with Apparent Early Stage Endometrial Cancer (EC) PI: Brian Slomovitz
Other Trials:
Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer. PI: Dr. Brian Slomovitz
Phase 1b Study to Assess the Safety of PLX3397 (CSF1 Inhibitor) and Paclitaxel in Patients with Advanced Solid Tumors. PI: Dr. Marilyn Huang
Phase 1-2 Study of ADXS11-001 (Listeria Immunotherapy) or MEDI4736 Alone or in Combination in Recurrent/Metastatic Cervical Cancer or HPV+ Head & Neck Cancer. PI: Dr. Brian Slomovitz
